Mycobacterium tuberculosis strains resistant to two or more of the first line antituberculosis drugs (MDR) are a serious threat to successful tuberculosis control programmes. For this retrospective study, 85 follow-up drug resistant isolates from 23 patients residing in a community with a high incidence of tuberculosis were collected and the level of in-vitro resistance to antibiotics determined quantitatively. PCR-SSCP and sequencing techniques were used to screen for gene mutations associated with resistance in 31 follow-up samples from a smaller group of eight patients. DNA fingerprint analysis was done on sequential isolates to confirm identity. Although treatment had a profound effect on changes in drug resistance patterns, the MIC for a particular agent remained constant in follow-up isolates. DNA fingerprinting and mutational analysis (14 different loci) showed that the genome of MDR strains of M. tuberculosis is relatively stable during the course of therapy. The rpoB gene was the most frequently mutated structural gene involved in drug resistance and a novel C to T mutation upstream of open reading frame (0RF)l of the inhA operon was detected. No evidence was found of the presence of strain W (New York) in this group of MDR strains. The results stress the importance of confirming individuality of strains for the accurate calculation of frequencies of particular mutations associated with drug resistance, particularly in a high incidence area. Approximately one-half (47.8%) of the patients had isolates resistant to concentrations just above the critical concentration for isoniazid (MICs of 0.2-5 mg/L). Therefore, these patients and their contacts who develop primary drug-resistant tuberculosis may respond to higher dosages of treatment which could have a considerable impact on the cost and the ease of management of resistant tuberculosis.
Introduction
A recent resurgence in the incidence of tuberculosis in developed and developing countries, linked partly to the human immunodeficiency virus (HIV) pandemic, has re-awakened public concern. Strains resistant to one or more of the major antituberculosis drugs threaten tuberculosis control programmes in developing and developed countries. Multidrug-resistant (MDR) strains have been associated with rapid progression to death of HIV-infected individuals [ 1, 21 and transmission of MDR strains to health care personnel is an added cause for concern. Streptomycin (SM) was the first drug shown to be effective in the treatment of tuberculosis [ 31. However, monotherapy led to the selection of resistant strains of Mycobacteriurn tuberculosis [4] and subsequently combination chemotherapy was shown to prevent the development of drug resistance. A combination of isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA) (the first-line drugs) is currently used with success in short course chemotherapy of tuberculosis. Various other drugs, such as SM or other aminoglycosides, ethionamide (ETH), ethambutol (EMB), thiacetazone (TH) and cycloserine ( C S ) are considered as alternatives for the management of MDR tuberculosis. Resistance to INH arises at a frequency of 10-5-10-7 comparable to that reported for RMP [5] . RMP is essential in short course chemotherapy regimens as, without it, treatment must be prolonged to 9 or 12 months to ensure sterilisation of the lesions. In developing countries the management of tuberculosis becomes extremely difficult in the presence of significant RMP resistance. A better understanding of the mechanisms leading to the development of MDR is essential to minimise this problem.
Mechanisms responsible for resistance to the first-line drugs have been the focus of research by many investigators and have been reviewed recently [6] . Resistance to INH develops as a result of mutations in the catalase-peroxidase gene (katG) or the inhA gene, which encodes an enzyme involved in mycolic acid synthesis. Resistance to ETH may also be mediated by mutations in the inhA gene. RMP resistance is mediated by mutations in the rpoB gene encoding the P-subunit of RNA polymerase. SM resistance can occur as a result of mutations in either the rrs gene or the S12 ribosomal protein gene (rpsL). It has been proposed that resistance in MDR strains is the result of an accumulation of mutations in the gene targets of a specific antibiotic. This may suggest a degree of inherent genome instability in these strains and implies that second-line drugs may also be of limited use, as their use may rapidly lead to resistance to these agents. Given this situation, it is essential that the use of first-line drugs such as INH and RMP be optimised.
To test the genome-instability hypothesis, the genome of serial M. tuberculosis isolates from patients in a high incidence community was studied by DNA fingerprinting and by mutational analysis of genes previously shown to be involved in resistance. The level of in-vitro resistance amongst MDR strains to antituberculosis drugs was also quantified.
Materials and methods

Clinical isolates and patient data
Drug-resistant isolates of M. tuberculosis (n = 85; group A samples, Table 1 ) were obtained during the follow-up of 23 patients residing in the Western Cape Province, South Africa, between Oct. 1993 and Aug. 1994 and the degree of in-vitro resistance to antituberculosis drugs was determined quantitatively for INH, RMP, SM and ETH. Follow-up isolates (n = 3 1; group B samples, Table 2 ) from a smaller group of eight patients were subjected to further molecular analysis. DNA fingerprint analysis with the IS61 10 probe was performed on all sequential isolates to confirm identity. All patients had evidence of tuberculosis on chest radiography and diagnosis was confirmed by culture of M. tuberculosis from sputum. The clinical isolates were resistant to at least one antituberculosis drug as determined by the proportional methods [7] . The susceptibility tests were performed on Lowenstein Jensen (LJ) medium containing critical concentrations (mg/L) of: INH, 0.2 and 1; RMP, 30; rifabutin (RBU), 10 and 20; SM, 5; ETH, 20; EMB, 2; ofloxacin (OF), 2; while kanamycin (KM) at, 5; CS, 50; and TH, 2 mg/L respectively were incorporated into Middlebrook 7HlO agar. Although all patients had active tuberculosis for periods longer than indicated in Tables 1 and 2, only the follow-up samples listed here were available and used for this study.
Quantitative drug resistance determination
The MICs of INH, RMP, SM and ETH were determined by the agar dilution method [8] . Serial dilutions of INH, RMP, SM and ETH were made and incorporated into Middlebrook 7H 10 agar medium. Test organisms, maintained on LJ medium, were inoculated into Dubos broth and incubated for 10 days at 37°C. The cultures were then adjusted to an optical density of a McFarland no. 1 standard, equivalent to c. 2 X lo7 organisms/ml, with a Klett-Summerson colorimeter. Ten pl of each culture were then inoculated (in duplicate) on to drug-containing and drug-free control plates, sealed in plastic bags and incubated at 37°C for 21 days. The lowest drug concentration that inhibited the growth of > 99% of the bacterial population was considered to be the MIC. M. tuberculosis H37Rv (ATCC 27294) was included as a control. Critical concentrations of 0.2 mg/L for INH, 1 mg/L for RMP, 2 mg/L for SM and 5 mg/L for ETH were used to discriminate between susceptible and resistant isolates.
Semi-quantitative catalase assays
Test organisms were grown to an optical density of a McFarland no. 1, standard in 20 X 150-mm screwcapped tubes containing Dubos medium. Oneml of a mixture (1 : 1) of hydrogen peroxide 30% and Tween 80 10% solution, was applied to the surface of growth. After 5 min, the highest level (in mm) of the column of 0 2 bubbles generated was recorded [9] . The H37Rv strain of M. tuberculosis and uninoculated tube of medium were included as controls. Additional controls consisted of M. avium (ATCC 25291, low catalase) and M. gordonae (ATCC 14470, high catalase).
DNA extraction and fingerprinting
Sputum samples were grown in a BACTEC TB-460 System (Becton Dickinson, USA) and subcultured on LJ slants. Organisms were heat-killed at 80°C for 1 h before DNA extraction [lo] and fingerprinted by restriction fragment-length polymorphism with the IS6 1 10 element as described elsewhere [ 1 13.
Mutational analysis
Primers were synthesised to amplify small regions (c. 200 bp each) of the katG, inhA, rpoB, rrs and rpsL genes (Table 3) . A 50-ng sample of DNA from each isolate was amplified in a 100-p1 reaction mixture and 5 pl of the amplified products were subjected to SSCP (Table 5) . The low frequency of ETH resistance is probably a reflection of the restriction of its use to the management of drug-resistant tuberculosis in this region. lanes 3, 4) , B3 (5, 6), B6 (7-11), B7 (12-14) and B8 (15, 16) were fingerprinted with the IS6110 element. Lane 1, control strain MT14323.
Results
Treatment and drug resistance patterns
to a single strain rather than to multiple infections selected by therapy or re-infection with different strains. Six of the serial isolates (isolates from patients B2 and B7, Table 2 and isolates from patients A, E, 0 and U, Table 1 ) showed slight DNA fingerprint perturbations as a function of time. These variations could be either the result of replicative transposition (additional bands) or anomalies in PvuII restriction as a result of DNA methylation (band shifts) [16] . These small DNA fingerprint changes do not imply reinfection but rather suggest strain evolution and thus these results suggest that all patients were infected with only a single strain.
Identijication of mutations by PCR-SSCP
Primers were selected to amplify 14 different genetic loci in the group B isolates ( Table 2) where mutations that are associated with resistance to INH, ETH, RMP and SM were previously reported. Ten of these loci are in structural genes, while three sets of primers were directed towards putative promoter regions of the katG gene and the inhA operon. The results are summarised in Table 2 .
Structural genes. The rpoB gene was the most frequently mutated gene in this set of MDR clinical isolates (Table 2) . Although the precise nature of the rpoB gene mutations was not determined for most isolates in this study, the SSCP analysis suggests that the same mutation is present in sequential isolates from a particular individual, as the nature of the mobility shift remained constant. Sequence analysis indicated that the mobility shifts for all the isolates of patient B2 were due to codon 516 mutations, changing from GAC to GTC, and all the isolates of patients B4 and B6 were due to codon 531 mutations, changing from TCG to TTG.
Mutations were detected in the katG gene in isolates from five of eight patients (Table 2 ). An Arg463Leu mutation has been reported previously [12, 16, 181 and the presence of this mutation in isolates 320, 463, 5 13 and 508 ( Sequential isolates from two patients had both the Arg463Leu and the Ser3 15Thr mutation. PCR-SSCP analysis of amplified products or RTB5 1/3 1 showed the same change in all five sequential isolates of patient B6, but the specific nature of the mutation is as yet unconfirmed. No mutations were detected in the other regions of the katG gene investigated in this study. Complete deletion of the katG gene has been proposed as a mechanism of resistance to INH [15] , but as several different regions of the gene could be amplified in this study, it can be concluded that none of the samples tested had significant katG gene deletions, thus confirming previous reports [6, 12, 171 . No differences in mutational spectrum were detected in serial isolates. The inhA gene may also be associated with resistance to INH, but no mutations were detected in a 169-bp region of the structural gene that has been shown previously to be involved in resistance to INH and ETH [19, 201. Mutations in both the rrs and rpsL genes are associated with resistance to SM and in both cases the mutations are located in two regions of these genes: codons 43 or 88 for rpsL and mutations located near or in codons 530 or 915 of rrs [21] . PCR-SSCP analysis of the rpsL region showed mobility shifts for all the isolates from patients B3 and B4. Restriction endonuclease analysis with Mbo I1 confirmed that the shifts were due to an A to G mutation at codon 43. No mutations were detected at codon 88 by SSCP or Hph I (codon 88) restriction endonuclease analysis. All the sequential isolates from patients B1 and B8 showed an A to C mutation at position 513 (confirmed by sequence analysis) of the rrs gene. Restriction endonuclease analysis with Rsa I (position 49 1) and BsrI (position 512) did not identify any further mutations in the 530 region and no mutations were identified in the 950 region of the rm gene in this group of MDR isolates.
The mutation at codon 43 in the rpsL gene is associated with a high level of resistance (MIC > 1000 mg/L) for SM in isolates from both patients B3 and B4 (Table 2) . DNA fingerprint analysis indicated that these two patients were infected with the same strain of M. tuberculosis (see DNA fingerprint analysis). It was subsequently found that isolates from patients G, H, P, T, Q and S (Table 1) which had similar MICs for SM, also had the codon 43 mutation. Although isolates f'rom patient N had fingerprints similar to those of isolates from patients G, H, P and T, they (from patient N) not only lacked this mutation, but also had considerably lower MICs. The precise mutation is not yet known.
Isolates from patients Q and S also had high MICs for SM. Unfortunately, no fingerprint data were available for isolates from patient Q (see DNA fingerprint analysis), but it was noted that the fingerprint patterns of isolates from patient S (six IS61 10 bands) differed by only one additional IS61 10 element compared to isolates from patients G, H, N, P and T (these had five IS6 1 10 elements). Futhermore, isolates from patients B1 and B8 (Table 2 ) also had the same mutations in drug resistance genes and showed the same DNA fingerprint pattern. These data suggest that certain mutations are associated with given levels of resistance and, furthermore, that although DNA fingerprint analysis is a useful technique to monitor the spread of disease, it has no direct diagnostic application, as strains with the same or similar DNA fingerprint patterns may or may not be drug resistant.
Mutations in the putative control elements. To determine whether mutations in control elements of relevant known genes may play a role in drug resistance, a domain spanning c. 400 bp upstream of the katG gene However, four of five sequential isolates from patient B2 showed a mobility shift in the putative control region of the inhA gene (Table 2) . Sequence analysis (Fig. 2) confirmed that the mobility shift was due to a novel C to T mutation at nucleotide -34 upstream of ORFl of the inhA operon. It is important to note that despite the identical fingerprints of all the isolates from this patient, no mutation was detected in isolate 45, the first isolate collected from this patient, which was susceptible to ETH according to the criteria used in this study. Further analysis of 15 other ETH-resistant isolates from this community failed to show this particular mutation.
Has strain W (New York) spread to our community?
Some of the MDR strains originating from this community in South Africa have similar drug resistance patterns and a high IS61 10 copy number which is similar to the highly drug-resistant M. tuberculosis strain W which has spread from New York to other cities in America and to France [22] . One of the striking features of strain W is a rare dinucleotide missense mutation at codon 315 (AGC to ACA) of the katG gene [22] . PCR amplification of this region and dot-blot hybridisation assays with radiolabelled oligonucleotides RTB39 (normal for codon 315 [12] ) and RTBmu (dinucleotide mutant for codon 3 15) were used to analyse the codon 315 region in one isolate from each of the patients Bl-B8 in Table 2 . Another 14 MDR isolates, which were not part of isolates in Tables 1 and 2, but which had a high IS61 10 copy number, were also examined. All the samples hybridised 45 strongly to oligonucleotide RTB39 and no hybridisation was observed with primer RTBmu under stringent conditions (results not shown), suggesting that none of these isolates belonged to the strain W family. However, this does not exclude the possibility that other members of this family which have undergone clonal expansion are present in our community [22] .
Discussion
It has been shown previously in limited studies that the DNA fingerprints of M. tuberculosis isolates from patients undergoing chemotherapy do not change during the development of resistance [23] . The results of DNA fingerprinting and mutational analysis (14 different loci) in the present study show that the genome of MDR M. tuberculosis strains is relatively stable, even while under pressure from different drugs during treatment. Furthermore, the acquisition of resistance to antituberculosis drugs in these patients is not due to secondary infection with a new resistant strain.
RpoB was the most frequently resistant M. tuberculosis and target for rapid molecular tuberculosis. There have been mutated gene in drug this gene is a useful screening for MDR many reports on the incidence of mutations in structural genes associated with drug resistance in M. tuberculosis [6, 12, 211. Only the presence and stability of specific mutations in these genes in serial isolates have been investigated in the present study and the results are not an indication of the frequency of the overall mutational pattern in drug-resistance genes in M. tuberculosis. However, this study enphasises the importance of confirming strain identity with fingerprint analysis at (Table 2) were amplified with primer set inhp5/inhp3 (Table 3) all times when reporting on the overall incidence of given mutations. This is particularly important when samples originate from a high incidence community for tuberculosis (700/ 100 000 cases/year), such as in South Africa [24] or when samples are analysed retrospectively from a databank.
Mutations in promotor regions of genes can potentially affect expression and, therefore, also contribute towards drug resistance. This possibility was investigated in the katG and inhA genes. However, none of the samples showed any mutations in the promoter sequences immediately upstream of the katG gene. This result is consistent with an earlier report where the isolates originated from a different geographical area [17] . In contrast, a novel C to T mutation at nucleotide -34 upstream of ORFl of the inhA operon was detected. This mutation, which has not been described previously, falls within the promotor region of this operon and could affect transcription and drug response, as the first isolate from patient B2 did not have the mutation at position -34 bp and only this isolate in the batch from one patient was susceptible to ETH. Mutations 1 bp on either side of a putative ribosome binding site of ORFl in inhA have been reported [6, 251, and although we have found the same mutations in other South African isolates (results not shown), these mutations were not detected in these particular isolates. Results from this study support accumulated evidence [6, 19, 251 that mutations in the structural region of the inhA gene are rare. Although mutations in the promotor region have been described in this paper and by others, few ETH-resistant samples have these promotor mutations. However, recent biochemical and genetic evidence suggests that inh A may not be the major target for activated INH in M. tuberculosis [26] and may explain why only some of the isolates have inhA mutations.
Accurate drug susceptibility testing of M. tuberculosis by conventional techniques is difficult and may perhaps explain the intermittent resistance patterns in follow-up isolates observed in this study. The development of antituberculosis drug resistance is best prevented by combination chemotherapy administered under direct observation. Failure to comply with this requirement on the part of the health services or the patient may lead to monotherapy. The use of combinations of drugs that do not offer optimal protection against the selection of drug-resistant mutants may also elicit resistance in some instances. This study illustrates the manner in which the sequential addition of drugs to the therapeutic regimen can be followed by the accumulative acquisition of resistance.
It is significant that despite changes in drug resistance patterns that occurred during treatment, the level of resistance (based on MICs) for a particular antibiotic remained constant in our patients. This has beep observed previously [27] and is an important consideration for treatment, as the results show that although the MICs are above the normal in-vitro critical concentrations for M. tuberculosis, a significant number of these organisms have MICs at achievable in-vivo concentrations and patients may still respond to treatment with these antibiotics, particularly if higher, but still clinically acceptable dosages of agents are used. The low MICs found in c. 50% of the INH-resistant isolates indicate that this agent, given in a higher dose, may still be active in many MDR tuberculosis patients [28] . Evidence fkom early clinical trials in which INH was used as the sole agent in patients with INH-resistant organisms suggests that the use of higher dosages of INH in patients with lower levels of resistance may be clinically beneficial [27] . However, it is known that the rate of elimination of INH is under genetic control [29, 301 and varies greatly from one individual to another. The rate of acetylation should therefore be taken into account in evaluating the activity of INH in MDR tuberculosis.
It is noteworthy that almost half of the isolates evaluated in this study were susceptible in vitro to concentrations of INH which are easily achievable, even in rapid acetylators of INH. As INH is relatively inexpensive compared to other drugs available for the management of MDR tuberculosis, we suggest that MIC (INH) testing of drug resistant strains of M. tuberculosis should be considered and that, where appropriate, INH should be included in any multidrug regimen for the treatment of MDR tuberculosis [28] . Given the limited number of drugs available for the management of MDR tuberculosis and the increased costs and toxicity associated with their use, it is important to take note of existing drugs that could possibly be used in a mutidrug regimen to treat a signficant proportion of the cases detected.
